Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cancer Therapies02:49

Cancer Therapies

7.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Poliovirus receptor (PVR) expression as a predictor of relapse in colorectal cancer: bioinformatics and virtual screening.

Experimental biology and medicine (Maywood, N.J.)·2026
Same author

Multi-target therapeutic potential of Neem (<i>Azadirachta indica</i>) phytochemicals in Alzheimer's disease: an integrative network pharmacology and molecular dynamics simulation approach.

In silico pharmacology·2025
Same author

Indazol-Pyrimidine Hybrids: Design, Synthesis, and Antiproliferative Activity Against Human Cancer Cell Lines.

Molecules (Basel, Switzerland)·2025
Same author

Mitigating Cadmium Toxicity: The Therapeutic Potential of Lactobacillus acidophilus Pro4 in Mice.

Probiotics and antimicrobial proteins·2025
Same author

Design, synthesis, biological evaluation and in silico studies of 2-anilino- 4-(benzimidazol- 1-yl)pyrimidine scaffold as antitumor agents.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society·2025
Same author

Synthesis, <i>in vitro</i> and <i>in silico</i> studies of a novel chrysin-ferrocene Schiff base with potent anticancer activity <i>via</i> G1 arrest, caspase-dependent apoptosis and inhibition of topoisomerase II.

Journal of enzyme inhibition and medicinal chemistry·2025

Related Experiment Video

Updated: Aug 2, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K

Crizotinib: A comprehensive profile.

Ahmed A Abdelgalil1, Hamad M Alkahtani2

  • 1Central Laboratory, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia.

Profiles of Drug Substances, Excipients, and Related Methodology
|April 15, 2023
PubMed
Summary
This summary is machine-generated.

Crizotinib, the first anaplastic lymphoma kinase (ALK) inhibitor, treats ALK-positive metastatic non-small cell lung cancer (NSCLC). This review covers its properties, analysis, pharmacology, and chromatographic separation methods.

Keywords:
ADME profilesCrizotinibHigh performance liquid chromatographyMethods of chemical synthesisPharmacological effectsPhysical profilesStability

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K

Related Experiment Videos

Last Updated: Aug 2, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K

Area of Science:

  • Oncology
  • Pharmacology
  • Analytical Chemistry

Background:

  • Crizotinib is a targeted therapy approved for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).
  • It was the first approved inhibitor targeting ALK, marking a significant advancement in personalized cancer treatment.
  • ALK-positive NSCLC represents a specific subset of lung cancer where targeted inhibition is effective.

Purpose of the Study:

  • To provide a comprehensive review of crizotinib.
  • To detail its nomenclature, physiochemical properties, preparation, and identification.
  • To explore qualitative and quantitative analytical techniques, pharmacology, and chromatographic separation methods.

Main Methods:

  • Literature review of existing studies and data on crizotinib.
  • Compilation of information on chemical and physical properties.
  • Analysis of pharmacological data and separation techniques, particularly chromatography.

Main Results:

  • Crizotinib's role as a pioneering ALK inhibitor in NSCLC treatment is established.
  • A detailed overview of crizotinib's characteristics, including its chemical and physical attributes, is presented.
  • Various analytical and chromatographic methods for crizotinib assessment and separation are reviewed.

Conclusions:

  • Crizotinib remains a key therapeutic agent for ALK-positive NSCLC.
  • Understanding its comprehensive profile is crucial for effective clinical application and further research.
  • The review highlights the importance of analytical and separation techniques in drug characterization and quality control.